CERRITOS, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Today, the Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) have announced their executives’ participation in multiple panel presentations at the upcoming APG 2024 Spring Conference in San Diego. Chief Medical Officer, Dr. Yale Podnos, will be discussing artificial intelligence and its uses in an oncology practice in the breakout session panel “AI on the Front Lines: Improving Outcomes and Reducing Costs for Complex Patients”. Dr. Daniel Virnich, Chief Executive Officer, will join other industry leaders on another panel, “Assuming Global Risk for Pharmaceuticals.”
About The Oncology Institute
Founded in 2007, The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 110+ employed clinicians and over 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Investors at Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.16 |
Daily Change: | 0.22 11.34 |
Daily Volume: | 932,229 |
Market Cap: | US$163.210M |
March 24, 2025 November 13, 2024 November 11, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load